Benperidol

DB12867ApprovedWithdrawnSmall molecule

Benperidol is a neuroleptic butyrophenone derivative indicated in the treatment of psychoses, manic episodes, and psychomotor agitation. Benperidol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.

Mechanism: Pharmacologically active on Dopamine receptor D2
Curator reviewed
Formula / weight: C₂₂H₂₄FN₃O₂ · 381.451 g/mol (avg)
Code names: CB 8089 · MCN-JR-4584 · R-4584

Resolves to

Compound

UNII97O6X78C53CAS2062-84-2ChEMBLCHEMBL297302ChEBI93403PubChem16363

Clinical / RWD

RxNorm1373ATCN05AD07

Structure

InChIKeyFEBOTPHFXYHVPL-UHFFFAOYSA-NSMILESOC1=NC2=CC=CC=C2N1C1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1

Targets

P14416DRD2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

727Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

3Structured indicationsCondition, population, route and combination as fields, not prose

3ContraindicationsEach with its own population and attribute set

16Marketed productsAcross 2 countries and 1 labeller

1ATC codeIncluding every combination product, plus 14 drug categories

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Benperidol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In